

National Cancer Policy Forum Workshop Ensuring Patient Access to Cancer Drugs

Peter B. Bach, MD, MAPP

Memorial Sloan Kettering Cancer Center

Planning Committee Chair

June 9, 2014

Session 1, 8:15 AM

Trends in Oncology Care

- Moderator: Barry Fortner, ION Solutions
 - Escalating Drug Prices
 - Kalipso Chalkidou, NICE International (via webex)
 - Consolidation of practices in hospital partnerships/changing of oncology practice
 - Bruce Gould, Community Oncology Alliance
 - The Financial Toxicity of Cancer Treatment: Can Patients Cope with Costs?
 - Yousuf Zafar, Duke University Medical School, Duke Cancer Center
 - Drug Shortages
 - Peyton Howell, Amerisource Bergen
 - CMS reimbursement policies in oncology
 - Marc Hartstein, Center for Medicare & Medicaid Services

Keynote Address, 11:00 AM

- Pharma pricing practices and the case for market self correction
 - Alex Bastian, GfK Custom Research, LLC

Session 2, 12:15 PM

Paradoxes of Cancer Drug Reimbursement

- Moderator: Jeffrey Ward, Swedish Cancer Institute
 - Brand name drugs v. generics
 - Jeffrey Peppercorn, Duke University Medical School
 - Oral vs. IV drugs
 - Lee Newcomer, United Health Group
 - 340b vs. everyone else
 - Rena Conti, University of Chicago
 - Private Practice v. hospital-based care
 - Eric Hammelman, Avalere Health
 - Variable co-insurance and premiums
 - Michael Kolodziej, Aetna

Session 3, 3:00 PM

Value and Policy Options

- Moderator: Scott Ramsey, Fred Hutchinson Cancer Center
 - The Patient Perspective
 - Shelley Fuld Nasso, National Coalition for Cancer Survivorship
 - Value based insurance design
 - Mark Fendrick, University of Michigan Center for Value Based Insurance Design
 - Bundling of Payments
 - Thomas Feeley, MD Anderson Cancer Center
 - Value-based drug pricing
 - Patricia Danzon, The Wharton School, University of Pennsylvania
 - Lessons from the Health Evidence Review Commission, Oregon Health Authority
 - Kevin Olson, Providence Cancer Center

No more chemor. Docs say it's not so

fa

T

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

In the news

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

Stacie B. Dusetzina, Aaron N. Winn, Gregory A. Abel, Haiden A. Huskamp, and Nancy L. Keating

By Scott Ramsey, David
Polly Newcomb, William


November 8, 2012

Washing Found T
**Sanofi Halves Price of Cancer Drug
Zaltrap After Sloan-Kettering Rejection**

By ANDREW POLLACK



For Bankruptcy than people
Without A Cancer Diagnosis

Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965 - 2014



Source: Peter B. Bach, MD, Memorial Sloan-Kettering Cancer Center

Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965 - 2014



Source: Peter B. Bach, MD, Memorial Sloan-Kettering Cancer Center

A Tale of Two Drugs

	Dalipi	Dylogia
ORR	50% (42%, 59%) 61% (52%, 70%)	54.6% (47, 62) 43.6% (36, 52)
Duration of response (months)	9.7 (1.4+, 9.7+) 11.1 (0.9+, 17.7+)	7.4 (5.4, 10.1) 7.1 (5.6, NE)
Reasonable side effect profile	YES	YES
Frequency	twice per day	once per day
Approval required RCT	NO	NO
Number of approval trials	2	1
Total sample size	255	163
First in class	NO	YES
Companion diagnostic codeveloped	YES	NO
Which should cost more?		---
Cost (\$2013, at approval)	\$11,375	\$13,276

Thank You